Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Baldan is active.

Publication


Featured researches published by Anna Baldan.


The American Journal of Gastroenterology | 2008

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.

Adriana Sergio; Chiara Cristofori; Romilda Cardin; Giorgio Pivetta; Roberto Ragazzi; Anna Baldan; Lisa Girardi; Umberto Cillo; Patrizia Burra; Anna Giacomin; Fabio Farinati

OBJECTIVE:Although transcatheter arterial chemoembolization (TACE) is effective in hepatocellular carcinoma (HCC), it is not considered a curative procedure. Among the factors potentially interfering with its effectiveness is a hypothetical neoangiogenic reaction due to ischemia. In our study, we evaluated the changes in the levels of two angiogenic factors (vascular endothelial growth factor [VEGF] and basic fibroblast growth factor [b-FGF]) and one parameter of invasiveness (urokinase-type plasminogen activator [uPA]) in patients treated with TACE.METHODS:Three blood samples were provided from 71 HCC patients undergoing TACE: before TACE (t0), after 3 days (t1), and after 4 wk, when they had spiral computed tomography (sCT) scanning (t2). The referring radiologists blindly evaluated tumor burden and vascularization at t0 and residual activity at t2. The choice of TACE as treatment was based on the American Association for the Study of Liver Diseases (AASLD) guidelines.RESULTS:Complete response at sCT was recorded in 27% of patients; mean survival was 35 months (confidence interval [CI] 31–40) and the 4-yr survival was 57%. VEGF levels were significantly correlated with the number of nodes and were higher in nonresponders at t2 (P = 0.01); below-median VEGF levels predicted a longer survival (P = 0.008). b-FGF correlated with VEGF, tumor size, vascularization, and residual activity, showing a borderline correlation with survival. uPA correlated with tumor size and VEGF. VEGF was singled out in the Cox multivariate analysis as an independent predictor of survival.CONCLUSIONS:When TACE is not totally effective, it may induce a significant neoangiogenetic reaction, as suggested by an increase in VEGF and b-FGF following treatment; this affects patient survival. VEGF emerges as the most reliable prognostic parameter, so it could be measured for judging TACE efficacy. Finally, antiangiogenic drugs may be indicated in TACE-treated HCC.


The American Journal of Gastroenterology | 2006

Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Chiara Cantarini; C. Cursaro; G.L. Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani

BACKGROUND:The clinical usefulness of α-fetoprotein (AFP) in hepatocellular carcinoma (HCC) management is debatable.OBJECTIVES:To assess, in a large multi-centric survey, diagnostic and prognostic reliability of AFP, predictive factors, and any correlation with the tumor immunophenotype.METHODS:A total of 1,158 patients with HCC were analyzed with reference to serum AFP levels at diagnosis. We evaluated: HCC grading, histotype, and size; Okuda, tumor–nodes–metastases (TNM), and Child-Pugh scores; liver function, symptoms, presence of metastases or portal thrombosis, etiology, survival, and treatment. In 66 patients with histological diagnosis, the pathologists evaluated p53 overexpression, MIB 1 labeling index, BCL-2 positive cells (index of apoptosis), and CD44 (adhesion molecule) positivity.RESULTS:Patients were divided into three AFP groups: normal (<20 ng/mL) [46%], elevated (21–400 ng/mL) [36%], and diagnostic (>400 ng/mL) [18%]. Statistical correlations were significant for: weight loss (P = 0.0056), pain (P = 0.0025), Child-Pugh score (P = 0.001), tumor size, Okudas and TNM stages, metastases, thrombosis, type of treatment (all p < 0.0001), and female sex (p < 0.004). AFP correlated with survival overall, in patients untreated, transplanted, or undergoing locoregional treatments; but not in those surgically treated. In the discriminant analysis, the related variables were size, female sex, Child-Pugh score, TNM staging (steps 1–4). When using the receiver operating characteristic curve, the prognostic reliability of AFP was limited with area under the curve of 0.59. Finally, patients with low expression of BCL2 had high AFP levels (p < 0.05). AFP positively correlated with Edmonson score (p < 0.0001).CONCLUSION:The evaluation of this large series of HCC patients allowed us to: confirm the low sensitivity (54%) of AFP in the diagnosis of HCC and its prognostic value, albeit limited, being tumor size, female sex (intriguingly enough), Child-Pugh score, and TNM staging independent predictors.


European Journal of Cancer Prevention | 2009

Gastrointestinal stromal tumors: Report of an audit and review of the literature

Guido Biasco; Daniela Velo; Imerio Angriman; M. Astorino; Anna Baldan; Matteo Baseggio; Umberto Basso; G. Battaglia; Matteo Bertin; Roberta Bertorelle; Paolo Bocus; Piero Brosolo; Andrea Bulzacchi; Renato Cannizzaro; Gian Franco Da Dalt; Monica Di Battista; Domenico Errante; Marny Fedrigo; Sergio Frustaci; Ivana Lionetti; Marco Massani; Roberto Mencarelli; Maria Cristina Montesco; Lorenzo Norberto; Maria Abbondanza Pantaleo; Claudio Pasquali; Davide Pastorelli; Carlo Rossi; Cesare Ruffolo; Luigi Salvagno

Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M : F=1 : 1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50% of the cases the tumor was smaller than 5 cm, whereas major symptoms were observed in 43% of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25% of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21%) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.


Alimentary Pharmacology & Therapeutics | 2006

Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma

Anna Baldan; Dario Marino; M. De Giorgio; C. Angonese; Umberto Cillo; A. D'alessandro; A. Masotto; M. Massani; M. Mazzucco; E. Miola; D. Neri; D. Paccagnella; G. Pivetta; A. Stellato; L. Tommasi; F. Tremolada; A. Tufano; G. Zanus; Fabio Farinati

Radiofrequency thermal ablation is the first therapeutic option in percutaneous treatment of hepatocellular carcinoma but data on its long‐term efficacy and safety are not conclusive.


Journal of Internal Medicine | 2005

Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.

S. Gianni; A. Cecchetto; G. Altavilla; R. Ragazzi; M. Bertazzo; M. De Giorgio; Anna Baldan; S. Fagiuoli; Fabio Farinati

Background/aims.  The prognosis of hepatocellular carcinoma (HCC) on cirrhosis is hard to predict as it depends on tumour stage, underlying liver disease, type of treatment and, possibly, biological factors of the tumour itself.


Journal of Feline Medicine and Surgery | 2017

Semen quality and interval to sterility in tom cats treated with a 9.4 mg deslorelin implant

Stefano Romagnoli; Anna Baldan; Camilla Righetti; Chiara Milani; Antonio Mollo; Calogero Stelletta

Objectives Gonadotropin-releasing hormone (GnRH) agonists like deslorelin are being increasingly used in tom cats for their efficacy in controlling reproductive behaviour and fertility. Deslorelin implants have been widely available in Europe since 2008. Little, if anything, is known about the interval between treatment and onset of sterility, as well as semen quality, after treatment in tom cats. The purpose of this study was to investigate semen quality and interval to sterility in tom cats treated with a 9.4 mg deslorelin implant. Methods Fifteen healthy adult tom cats were treated with a 9.4 mg deslorelin implant (Suprelorin 12). For each cat, semen collection and a GnRH stimulation test (intramuscular administration of 50 μg gonadorelin [Fertagyl], followed by blood sampling 1 h later, to assay serum testosterone) were performed on the first consultation and then repeated every 15 days until complete sterility was achieved. Semen collection was performed by introducing a 14 cm, open-end feline catheter (Argyle) 9 cm into the distal urethra 10 mins after sedation by intramuscular injection of 100 μg/kg medetomidine (Domitor). Results Semen collection was not successful in all cats at each attempt. In the first month after treatment, the semen of only four cats could be evaluated, while the semen of eight cats could be evaluated during the second and third months of the study. Semen quality (ejaculate volume, progressive motility and morphological abnormalities) improved slightly during the first 19–25 days in 2/4 cats, and in 1/4 cats motility was still very high (80%) 25 days post-treatment (PT), but we have no data regarding fertility prior to treatment in this cat. The last cat never produced spermatozoa. Subsequently, semen quality gradually worsened in all cats from 30 days onwards. At 70 days PT, one cat was still potentially fertile. After 72 days all cats were sterile. Conclusions and relevance Semen quality increased slightly in treated cats during the first month after treatment, and then gradually decreased over the following months. Complete sterility was reached within 40–72 days following implantation.


Journal of Feline Medicine and Surgery | 2017

Postponement of puberty in queens treated with deslorelin

Marta Cecchetto; Paola Salata; Anna Baldan; Chiara Milani; Antonio Mollo; Christelle Fontaine; Hasan Sontas; Donatella Gelli; Giulia Maria De Benedictis; Calogero Stelletta; Stefano Romagnoli

Objectives The purpose of this study was to assess efficacy of deslorelin, a gonadotropin-releasing hormone (GnRH) agonist marketed in Europe for the control of male dog reproduction, for the postponement of puberty in queens. Methods Nine prepubertal queens aged 3–9 months were selected for this study; their general and reproductive health was checked through clinical, haematological, vaginal cytology and hormonal tests. Following treatment with a 4.7 mg deslorelin implant, each cat received a monthly clinical examination and blood was collected for hormonal assay every third month. Cats were monitored for 14.1 ± 5.2 (range 7–23) months. Results All cats were in good body condition and normal health prior to treatment. Their health status remained unchanged throughout the study and no significant variation was observed with regard to serum progesterone or oestradiol. Seven days post-treatment, 1/9 queens showed signs of heat, and one other queen showed complete vaginal keratinisation. No other signs of heat were subsequently observed in any other queen. Five queens were lost during the study after 7, 7, 16, 17 and 18 months of observation (during which time they did not show signs of heat). By the end of the study, no sign of puberty was observed in the four remaining queens at 21–36 months of age. Conclusions and relevance A 4.7 mg deslorelin implant was able to suppress the feline pituitary–gonadal axis, leading to postponement of puberty for up to 21–36 months in the four queens that completed the study. Deslorelin can be considered as a safe method to postpone puberty in queens.


The American Journal of Gastroenterology | 2006

Alpha Fetoprotein in Hepatocellular Carcinoma: Reply to Letter to Editor

Fabio Farinati; Anna Baldan; Franco Trevisani

Any comment on -fetoprotein (AFP) determination as a surveillance or diagnostic tool for hepatocellular carcinoma (HCC) is welcome, given the debate on the topic and the need to definitely state whether or not the marker should continue to make part of the diagnostic tools for HCC and, consequently, we appreciated the letter by Colli and coworkers. In their comment to our paper (1), they state that the design of our study prevents an actual estimation on either the specificity or sensitivity of AFP as a seromarker of HCC in patients at risk (i.e., cirrhotics). They identify flaws in both the characteristic of patient enrolment (retrospective case series without mandatory histological confirmation of the tumor) and the use of a given value of the index test (AFP >400 ng/mL) as confirmatory test for HCC diagnosis in order to include patients in our series (incorporation bias).


BMC Cancer | 2009

Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study

Fabio Farinati; Adriana Sergio; Anna Baldan; Anna Giacomin; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnù; G.L. Rapaccini; Marco Zoli; Franco Borzio; Edoardo G. Giannini; Eugenio Caturelli; Franco Trevisani


Reproduction in Domestic Animals | 2017

Use of the gonadotropin-releasing hormone (GnRH) stimulation test to monitor gonadal function in intact adult male cats

Stefano Romagnoli; Anna Baldan; Camilla Righetti; Christelle Fontaine; L Scenna; Tamara Badon; Calogero Stelletta; Chiara Milani; Marta Cecchetto; Antonio Mollo

Collaboration


Dive into the Anna Baldan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G.L. Rapaccini

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge